CN112451486A - 用顺铂脂质复合物预防癌症的肺部复发 - Google Patents

用顺铂脂质复合物预防癌症的肺部复发 Download PDF

Info

Publication number
CN112451486A
CN112451486A CN202011157925.9A CN202011157925A CN112451486A CN 112451486 A CN112451486 A CN 112451486A CN 202011157925 A CN202011157925 A CN 202011157925A CN 112451486 A CN112451486 A CN 112451486A
Authority
CN
China
Prior art keywords
bone
inhalation
osteosarcoma
lung
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202011157925.9A
Other languages
English (en)
Chinese (zh)
Inventor
F·H·安东尼
M·M·帕里斯
E·J·托马斯
章广韬
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enkang Pharmaceutical Technology Guangzhou Co ltd
Foshan Intelgen Pharmaceuticals Co ltd
Eleison Pharmaceuticals LLC
Original Assignee
Eleison Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eleison Pharmaceuticals LLC filed Critical Eleison Pharmaceuticals LLC
Publication of CN112451486A publication Critical patent/CN112451486A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202011157925.9A 2012-09-04 2013-09-04 用顺铂脂质复合物预防癌症的肺部复发 Pending CN112451486A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261743398P 2012-09-04 2012-09-04
US61/743,398 2012-09-04
CN201380045971.1A CN105025904A (zh) 2012-09-04 2013-09-04 用顺铂脂质复合物预防癌症的肺部复发

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380045971.1A Division CN105025904A (zh) 2012-09-04 2013-09-04 用顺铂脂质复合物预防癌症的肺部复发

Publications (1)

Publication Number Publication Date
CN112451486A true CN112451486A (zh) 2021-03-09

Family

ID=50187920

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201380045971.1A Pending CN105025904A (zh) 2012-09-04 2013-09-04 用顺铂脂质复合物预防癌症的肺部复发
CN202011157925.9A Pending CN112451486A (zh) 2012-09-04 2013-09-04 用顺铂脂质复合物预防癌症的肺部复发
CN202210952065.0A Pending CN115414384A (zh) 2012-09-04 2013-09-04 用顺铂脂质复合物预防癌症的肺部复发

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201380045971.1A Pending CN105025904A (zh) 2012-09-04 2013-09-04 用顺铂脂质复合物预防癌症的肺部复发

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202210952065.0A Pending CN115414384A (zh) 2012-09-04 2013-09-04 用顺铂脂质复合物预防癌症的肺部复发

Country Status (10)

Country Link
US (1) US11291644B2 (enExample)
EP (1) EP2892524B1 (enExample)
JP (1) JP2015530387A (enExample)
CN (3) CN105025904A (enExample)
CA (1) CA2883703C (enExample)
DK (1) DK2892524T3 (enExample)
ES (1) ES2848025T3 (enExample)
MX (1) MX2015002842A (enExample)
PL (1) PL2892524T3 (enExample)
WO (1) WO2014039533A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9107824B2 (en) 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
JP2009539403A (ja) 2006-06-13 2009-11-19 オンコメッド ファーマシューティカルズ インコーポレイテッド 癌を診断および処置するための組成物および方法
US8088617B2 (en) 2007-01-24 2012-01-03 Oncomed Pharmaceuticals, Inc. Antibodies that bind the glutamate ligand binding region of Notch1
CA2729306C (en) 2008-07-08 2015-08-18 Oncomed Pharmaceuticals, Inc. Notch-binding agents and antagonists and methods of use thereof
ES2848025T3 (es) 2012-09-04 2021-08-05 Eleison Pharmaceuticals LLC Prevención de la recidiva pulmonar del cáncer con cisplatino complejado con lípidos
CA2917712C (en) 2013-07-08 2022-08-16 International Dehydrated Foods, Inc. Compositions prepared from poultry and methods of their use
US11478504B2 (en) 2013-07-08 2022-10-25 International Dehydrated Foods, Inc. Compositions and methods for preventing/treating metabolic syndrome
CA2941733A1 (en) * 2014-03-07 2015-09-11 Oncomed Pharmaceuticals, Inc. Methods for treating cancer with notch1 antibodies
CN109568336B (zh) * 2018-12-29 2021-10-08 江苏靶标生物医药研究所有限公司 一种铂类化合物和硫酸软骨素的组合物及其应用
KR20230155462A (ko) 2021-03-11 2023-11-10 칼로사이트, 인코포레이티드 체액으로부터 생합성 나노 입자를 제거하기 위한 조성물 및 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070065522A1 (en) * 2004-03-18 2007-03-22 Transave, Inc. Administration of high potency platinum compound formulations by inhalation

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993754A (en) 1974-10-09 1976-11-23 The United States Of America As Represented By The United States Energy Research And Development Administration Liposome-encapsulated actinomycin for cancer chemotherapy
GB1521000A (en) 1975-06-13 1978-08-09 Syntex Puerto Rico Inc Inhalation device
US4086257A (en) 1976-10-12 1978-04-25 Sears Barry D Phosphatidyl quaternary ammonium compounds
CH624011A5 (enExample) 1977-08-05 1981-07-15 Battelle Memorial Institute
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4529561A (en) 1978-03-24 1985-07-16 The Regents Of The University Of California Method for producing liposomes in selected size range
US4227522A (en) 1978-09-05 1980-10-14 Syntex Puerto Rico, Inc. Inhalation device
US4192309A (en) 1978-09-05 1980-03-11 Syntex Puerto Rico, Inc. Inhalation device with capsule opener
US4451447A (en) 1980-03-31 1984-05-29 Bristol-Myers Company Pharmaceutical formulations
US4522803A (en) 1983-02-04 1985-06-11 The Liposome Company, Inc. Stable plurilamellar vesicles, their preparation and use
US5435989A (en) 1982-03-30 1995-07-25 Vestar, Inc. Method of targeting a specific location in a body
LU85034A1 (fr) 1982-10-08 1985-06-19 Glaxo Group Ltd Dispositifs en vue d'administrer des medicaments a des patients
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
US4588578A (en) 1983-08-08 1986-05-13 The Liposome Company, Inc. Lipid vesicles prepared in a monophase
US4981692A (en) 1983-03-24 1991-01-01 The Liposome Company, Inc. Therapeutic treatment by intramammary infusion
US5030453A (en) 1983-03-24 1991-07-09 The Liposome Company, Inc. Stable plurilamellar vesicles
US5169637A (en) 1983-03-24 1992-12-08 The Liposome Company, Inc. Stable plurilamellar vesicles
US4590001A (en) 1983-03-28 1986-05-20 Stjernholm Rune L Platinum bound to transferrin for use in the treatment of breast tumors
USRE33071E (en) 1983-03-28 1989-09-26 Platinum bound to transferrin for use in the treatment of breast tumors
US4572425A (en) 1983-08-01 1986-02-25 Russell William S Reusable container
EP0153955A1 (en) 1983-09-06 1985-09-11 Health Research, Inc. Liposome delivery method for decreasing the toxicity of an antitumor drug
US4721612A (en) 1984-04-12 1988-01-26 The Liposome Company, Inc. Steroidal liposomes
US5008050A (en) 1984-06-20 1991-04-16 The Liposome Company, Inc. Extrusion technique for producing unilamellar vesicles
CA1270198C (en) 1984-08-08 1990-06-12 Marcel B Bally ENCAPSULATION OF ANTINEOPLASTIC AGENTS IN LIPOSONES
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4975282A (en) 1985-06-26 1990-12-04 The Liposome Company, Inc. Multilamellar liposomes having improved trapping efficiencies
US5059421A (en) 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
GB2178965B (en) 1985-07-30 1988-08-03 Glaxo Group Ltd Devices for administering medicaments to patients
JPH0665648B2 (ja) 1985-09-25 1994-08-24 塩野義製薬株式会社 白金系抗癌物質の安定な凍結真空乾燥製剤
US4861580A (en) 1985-10-15 1989-08-29 The Liposome Company, Inc. Composition using salt form of organic acid derivative of alpha-tocopheral
US5117022A (en) 1985-10-18 1992-05-26 The Board Of Regents, The University Of Texas System Hydrophobic cis-platinum complexes efficiently incorporated into liposomes
US5041581A (en) 1985-10-18 1991-08-20 The University Of Texas System Board Of Regents Hydrophobic cis-platinum complexes efficiently incorporated into liposomes
US5049388A (en) 1986-11-06 1991-09-17 Research Development Foundation Small particle aerosol liposome and liposome-drug combinations for medical use
US5320906A (en) 1986-12-15 1994-06-14 Vestar, Inc. Delivery vehicles with amphiphile-associated active ingredient
MX9203808A (es) 1987-03-05 1992-07-01 Liposome Co Inc Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
CA1338702C (en) 1987-03-05 1996-11-12 Lawrence D. Mayer High drug:lipid formulations of liposomal- antineoplastic agents
US5616334A (en) 1987-03-05 1997-04-01 The Liposome Company, Inc. Low toxicity drug-lipid systems
DE3852037T2 (de) 1987-07-29 1995-03-23 Liposome Co Inc Verfahren zur trennung von teilchen nach grösse.
IL83380A (en) 1987-07-30 1991-04-15 Teva Pharma Stable aqueous cisplatin solutions
DE68901733T2 (de) 1988-03-04 1993-03-25 Takeda Chemical Industries Ltd Liposom-zusammensetzung.
US5141751A (en) 1988-06-29 1992-08-25 Daiichi Pharmaceutical Co., Ltd. Lipid membrane structures
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5077057A (en) 1989-04-05 1991-12-31 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
JPH05963A (ja) 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
JP3220180B2 (ja) 1991-05-23 2001-10-22 三菱化学株式会社 薬剤含有タンパク質結合リポソーム
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
EP0551169A1 (en) 1992-01-10 1993-07-14 Takeda Chemical Industries, Ltd. Liposome composition and production thereof
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5958449A (en) 1992-12-02 1999-09-28 Nexstar Pharmaceuticals, Inc. Antibiotic formulation and use for bacterial infections
CN1088777A (zh) 1992-12-18 1994-07-06 丛繁滋 用于癌病灶直接给药的化疗药物制剂的制备方法
US5665383A (en) 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of immunostimulating agents for in vivo delivery
US5780054A (en) 1996-01-17 1998-07-14 University Of British Columbia Methods for increasing the circulation half-life of protein-based therapeutics
EP0896816A4 (en) 1996-02-26 2002-06-12 Daiichi Seiyaku Co LIPOSOME AND LIPOSOME DISPERSION
DK0910382T3 (da) 1996-04-26 2003-10-06 Genaera Corp Squalamin i kombination med andre anticancermidler til behandling af tumorer
ES2208946T3 (es) 1996-08-23 2004-06-16 Sequus Pharmaceuticals, Inc. Liposomas que contienen un compuesto de cisplatino.
US5997899A (en) 1996-10-01 1999-12-07 Skyepharma Inc. Method for producing liposomes with increased percent of compound encapsulated
AU7711096A (en) 1996-12-03 1998-06-29 Rijsuniversiteit Utrecht Cisplatinum comprising pharmaceutical
CA2628857C (en) 1996-12-30 2011-09-13 Batelle Memorial Institute Formulation and method for treating neoplasms by inhalation
US6451784B1 (en) 1996-12-30 2002-09-17 Battellepharma, Inc. Formulation and method for treating neoplasms by inhalation
UA71540C2 (uk) 1997-02-05 2004-12-15 Фармація Енд Апджон Компані Спосіб одержання ліпідних комплексів або ліпосом водонерозчинного діаміноциклогексанкарбоксилату платини та фармацевтична композиція, що містить ліпідний комплекс або ліпосоми водонерозчинного діаміноциклогексанкарбоксилату платини
FR2759293B1 (fr) 1997-02-11 1999-04-30 Ethypharm Lab Prod Ethiques Microgranules contenant du cisplatine, procede de fabrication, preparation pharmaceutique et utilisation en polychimiotherapie ou en association avec une radiotherapie
US6630168B1 (en) 1997-02-20 2003-10-07 Biomedicines, Inc. Gel delivery vehicles for anticellular proliferative agents
US6090407A (en) 1997-09-23 2000-07-18 Research Development Foundation Small particle liposome aerosols for delivery of anti-cancer drugs
US7348025B2 (en) 1997-09-23 2008-03-25 Research Development Foundation Small particle liposome aerosols for delivery of anticancer drugs
US6787132B1 (en) 1997-12-04 2004-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combined chemo-immunotherapy with liposomal drugs and cytokines
US6726925B1 (en) 1998-06-18 2004-04-27 Duke University Temperature-sensitive liposomal formulation
CA2248592A1 (en) 1998-08-31 2000-02-29 Christopher D. Batich Microspheres for use in the treatment of cancer
ES2156506B1 (es) 1998-10-14 2002-03-01 Sumitomo Chemical Co Metodo para la produccion de oxido de propileno.
EP1128813B1 (en) 1998-11-12 2007-02-14 Inc. Transave An inhalation system
US20050074499A1 (en) 1999-03-17 2005-04-07 Mitsubishi Chemical Corporation Ligand-bonded complex
US6723338B1 (en) 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
US6852334B1 (en) 1999-04-20 2005-02-08 The University Of British Columbia Cationic peg-lipids and methods of use
AU780454B2 (en) 1999-06-03 2005-03-24 Jessie L.S. Au Methods and compositions for modulating cell proliferation and cell death
US6352996B1 (en) 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US6800437B1 (en) 1999-08-06 2004-10-05 Tibotec Bvba Method of monitoring a biological system by labeling with an apo metal binding protein
US6511676B1 (en) 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
WO2001032139A2 (en) 1999-11-05 2001-05-10 Seed Capital Investment-2 (Sci-2) B.V. Method for the formulation of substances having a low water-solubility and lipophilicity and formulation thus obtained
RU2270683C2 (ru) 1999-12-04 2006-02-27 Рисерч Дивелопмент Фаундейшн Увеличение эффективности ингаляционной терапии с помощью диоксида углерода
EP1259225B1 (en) 2000-02-04 2006-10-04 Lipoxen Technologies Limited Process of dehydration/rehydration for making liposomes
EP1267834A4 (en) 2000-03-29 2003-08-27 Aradigm Corp CATIONIC LIPOSOMES
AU2001260270A1 (en) 2000-05-02 2001-11-12 Pharmacept Gmbh Liposomes containing active substances
US6998393B2 (en) 2000-06-23 2006-02-14 Biopharm Solutions, Inc. Aquespheres, their preparation and uses thereof
AU2001270385B2 (en) 2000-06-30 2006-05-25 Talon Therapeutics, Inc. Liposomal antineoplastic drugs and uses thereof
JP2004537501A (ja) 2001-02-01 2004-12-16 ボード　オブ　リージェンツ，　ザ　ユニバーシティ　オブ　テキサス　システム 肺への遺伝子送達のための安定化ポリマーエアロゾル
EP1383521A2 (en) 2001-04-23 2004-01-28 Nucryst Pharmaceuticals Corp. Medicament containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use to induce apoptosis in cancerous tissue
EP1320355B1 (en) 2001-05-18 2006-04-05 Chiron Corporation System for delivering a tobramycin formulation
US7063860B2 (en) 2001-08-13 2006-06-20 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
CA2457148A1 (en) 2001-08-20 2003-02-27 Transave, Inc. Treatment of cancers by inhalation of stable platinum-containing formulations
US20030059375A1 (en) 2001-08-20 2003-03-27 Transave, Inc. Method for treating lung cancers
CA2477982A1 (en) 2002-03-05 2003-09-18 Transave, Inc. Methods for entrapment of bioactive agent in a liposome or lipid complex
US20040022842A1 (en) 2002-06-03 2004-02-05 Mebiopharm Co., Ltd. Liposome preparations containing oxaliplatin
JP3415131B1 (ja) 2002-06-03 2003-06-09 メビオファーム株式会社 リポソーム製剤
BRPI0313191A2 (pt) 2002-08-02 2016-11-08 Transave Inc composição e processo para produzir um agregado de platina e formulação farmacêutica
US9186322B2 (en) 2002-08-02 2015-11-17 Insmed Incorporated Platinum aggregates and process for producing the same
SI1581236T1 (sl) 2002-10-29 2014-02-28 Insmed Incorporated Princeton Corporate Plaza Zadržano sproščanje antiinfektivov
CA2506746A1 (en) 2002-11-26 2004-06-10 Gilead Sciences, Inc. Method of drug loading in liposomes by gradient
EP1706148A2 (en) 2004-01-14 2006-10-04 Gilead Sciences, Inc. Lipid-based dispersions useful for drug delivery
EP1729786A4 (en) 2004-03-18 2008-03-26 Transave Inc ADMINISTRATION OF CISPLATIN BY INHALATION
US8221739B2 (en) * 2004-04-29 2012-07-17 Botanic Oil Innovations, Inc. Method of cancer treatment
AU2005245018A1 (en) 2004-05-21 2005-12-01 Transave, Inc. Treatment of lung diseases and pre-lung disease conditions
EP1811963A4 (en) 2004-11-08 2010-01-06 Transave Inc METHOD FOR CREATING TREATMENT WITH INTRAPERITONEALLY APPLIED PLATINUM COMPOUND FORMULATIONS ON LIPID BASIS
AU2005319508A1 (en) 2004-12-14 2006-06-29 Transave, Inc. Lipid particles comprising bioactive agents, methods of preparing and uses thereof
US20090202431A1 (en) 2005-04-08 2009-08-13 University Of Florida Research Foundation, Inc. Stem-like cells in bone sarcomas
WO2007056264A2 (en) 2005-11-08 2007-05-18 Transave, Inc. Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
US20090130194A1 (en) * 2005-11-08 2009-05-21 Transave, Inc. Methods of Treating Cancer with High Potency Lipid-Based Platinum Compound Formulations Administered Intravenously
US9107824B2 (en) 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
WO2007064658A2 (en) 2005-11-30 2007-06-07 Transave, Inc. Safe and effective methods of administering therapeutic agents
GR20060100144A (el) 2006-03-03 2007-10-17 Θεραπεια του καρκινου με χρηση οξαλιπλατινης εγκλεισμενης μεσα σε λιποσωματα και απο κοινου εγκλεισμος στο λιποσωμιακο μοριο περισσοτερων απο ενος φαρμακευτικου παρασκευασματος h gene
WO2010132847A1 (en) * 2009-05-14 2010-11-18 Oatmeal Biotechnologies Group, L.L.C. Platform technologies for spontaneously occurring diseases
CN107412749A (zh) 2010-02-22 2017-12-01 优势医疗公司 治疗脑的出血性病状的方法和组合物
WO2012009703A2 (en) * 2010-07-16 2012-01-19 Epeius Biotechnologies Corporation Targeted nanoparticles for cancer and other disorders
ES2848025T3 (es) 2012-09-04 2021-08-05 Eleison Pharmaceuticals LLC Prevención de la recidiva pulmonar del cáncer con cisplatino complejado con lípidos

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070065522A1 (en) * 2004-03-18 2007-03-22 Transave, Inc. Administration of high potency platinum compound formulations by inhalation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
A.J.CHOU ETAL: "Phase Ib/IIa study of sustained release lipid inhalation targeting cisplatin by inhalation in the treatment of patient with relapsed/progressive osteosarcoma metastatic to the lung", 《ASCO ANNUAL MEETING PROCEEDINGS JOURNAL OF CLINICAL ONCOLOGY》 *

Also Published As

Publication number Publication date
DK2892524T3 (da) 2021-01-25
ES2848025T3 (es) 2021-08-05
US11291644B2 (en) 2022-04-05
PL2892524T3 (pl) 2021-10-25
CN115414384A (zh) 2022-12-02
CA2883703A1 (en) 2014-03-13
JP2015530387A (ja) 2015-10-15
HK1212593A1 (en) 2016-06-17
EP2892524A2 (en) 2015-07-15
WO2014039533A3 (en) 2015-07-16
MX2015002842A (es) 2015-08-12
CA2883703C (en) 2021-10-19
EP2892524B1 (en) 2020-11-25
CN105025904A (zh) 2015-11-04
US20140065205A1 (en) 2014-03-06
EP2892524A4 (en) 2016-07-06
WO2014039533A2 (en) 2014-03-13

Similar Documents

Publication Publication Date Title
US11291644B2 (en) Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin
Fazil et al. Bisphosphonates: therapeutics potential and recent advances in drug delivery
Li et al. Advances in bone‐targeted drug delivery systems for neoadjuvant chemotherapy for osteosarcoma
TW200413000A (en) Intrinsic repair factor producing accelerator
KR20110132446A (ko) 키나아제 단백질 결합 억제제
Carneiro et al. Platelet-rich plasma gel promotes regeneration of articular cartilage in knees of sheeps
EP3024490A1 (en) Treatment of pancreatic cancer with a combination of a hypoxia-acti vated prodrug and a taxane
WO2004064785A2 (en) Cancer therapy sensitizer
KR102787188B1 (ko) 방광암에 대한 신보조 요법
Xu et al. Targeted inhibition of STAT3 (Tyr705) by xanthatin alleviates osteoarthritis progression through the NF-κB signaling pathway
Giordano et al. Nanodelivery systems face challenges and limitations in bone diseases management
JP4671962B2 (ja) デフィブロチド単独又は他の抗腫瘍剤との組み合わせを含む抗腫瘍製剤
JP2022064986A (ja) Ｌｌｐ２ａ－ビスホスホネート化合物を用いて骨壊死を処置する方法
Sellers et al. From conventional to cutting edge: An exploration of osteosarcoma treatments
Todd et al. LiF@ SiO2 nanocapsules for controlled lithium release and osteoarthritis treatment
Okui et al. Antitumor effect of temsirolimus against oral squamous cell carcinoma associated with bone destruction
Zhu et al. Bioengineering strategies targeting angiogenesis: Innovative solutions for osteonecrosis of the femoral head
De Cesare et al. Stimulation of the apoptotic response as a basis for the therapeutic synergism of lonidamine and cisplatin in combination in human tumour xenografts
Weber et al. Renal cell carcinoma bone metastasis: epidermal growth factor receptor targeting.
WO2014074529A1 (en) Methods for treatment of primary cancer and cancer metastasis
Dest Radioprotectants: adding quality of life to survivorship?
HK1212593B (en) Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin
Pilat et al. Vascular targeting agents
El-Abdaimi et al. Pamidronate prevents the development of skeletal metastasis in nude mice transplanted with human breast cancer cells by reducing tumor burden within bone
US20120171181A1 (en) Compositions and minimally invasive methods for treating cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20221116

Address after: Fla

Applicant after: ELEISON PHARMACEUTICALS, LLC

Applicant after: Enkang Pharmaceutical Technology (Guangzhou) Co.,Ltd.

Applicant after: FOSHAN INTELGEN PHARMACEUTICALS Co.,Ltd.

Address before: Fla

Applicant before: ELEISON PHARMACEUTICALS, LLC

TA01 Transfer of patent application right